CN115998974A - Plasma adsorption device for animal experiments - Google Patents
Plasma adsorption device for animal experiments Download PDFInfo
- Publication number
- CN115998974A CN115998974A CN202211674644.XA CN202211674644A CN115998974A CN 115998974 A CN115998974 A CN 115998974A CN 202211674644 A CN202211674644 A CN 202211674644A CN 115998974 A CN115998974 A CN 115998974A
- Authority
- CN
- China
- Prior art keywords
- pipeline
- plasma
- adsorption
- animal experiments
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 138
- 241001465754 Metazoa Species 0.000 title claims abstract description 58
- 238000002474 experimental method Methods 0.000 title claims abstract description 31
- 230000017531 blood circulation Effects 0.000 claims abstract description 37
- 239000012528 membrane Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000002572 peristaltic effect Effects 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims description 51
- 239000008280 blood Substances 0.000 claims description 51
- 239000007788 liquid Substances 0.000 claims description 17
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 229920000936 Agarose Polymers 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 210000004731 jugular vein Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 12
- 238000004140 cleaning Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 238000009832 plasma treatment Methods 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 description 89
- 229920000669 heparin Polymers 0.000 description 22
- 239000002504 physiological saline solution Substances 0.000 description 22
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 20
- 229960002897 heparin Drugs 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 230000008929 regeneration Effects 0.000 description 9
- 238000011069 regeneration method Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 230000010100 anticoagulation Effects 0.000 description 6
- 239000002351 wastewater Substances 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000008081 blood perfusion Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The invention discloses a plasma adsorption device for animal experiments, which is characterized in that a plasma adsorption treatment process is divided into two parts of whole blood circulation and plasma adsorption and adsorption column treatment, and a whole blood circulation pipeline and a plasma adsorption and adsorption column treatment pipeline are correspondingly arranged, so that on one hand, the cleaning and balance of the adsorption column can be realized under the condition of not influencing the whole blood circulation, the adsorption effect of the adsorption column on harmful components in the plasma treatment process is ensured, on the other hand, the arrangement of a first pressure gauge, a second pressure gauge and a third pressure gauge is utilized in combination, the pressure monitoring of the first pipeline, the second pipeline and the third pipeline is carried out, and the differential pressure of the three pipelines is controlled within a certain range through a first peristaltic pump and a second peristaltic pump, so that the blood pressure drop caused by the differential pressure of the pipelines and the rupture of a membrane type plasma separator are avoided, and the plasma adsorption device disclosed by the invention can be suitable for the plasma adsorption treatment of animals with the blood flow of more than or equal to 30 ml/min.
Description
Technical Field
The invention relates to the technical field of medical equipment, in particular to a plasma adsorption device for animal experiments.
Background
Hemodialysis has been a development history for over a hundred years, and blood purification is a technology developed on the basis of hemodialysis. The blood of the patient is led out of the body and passed through a purification device to remove some pathogenic substances, so as to purify the blood, and the goal of curing diseases is reached, and this process is called blood purification. Immunoadsorption belongs to a new treatment technology for purifying blood, and is mainly used for treating diseases which are difficult to treat by the traditional method. The principle is mainly to fix a certain antibody, antigen or some ligand with specific adsorption performance on a carrier, and selectively or specifically remove toxic proteins or other endogenous pathogenic factors in the blood of a patient by utilizing the adsorption performance of the ligand, thereby achieving the purposes of purifying the blood, relieving symptoms and treating diseases.
Unlike the whole blood adsorption mode of blood perfusion, immunoadsorption often employs plasma adsorption for therapeutic effects. In the case of plasma adsorption, the femoral vein of an animal is generally used for establishing an extracorporeal blood circulation path, the operation is complex and can not be used repeatedly, and the damage to the animal is also large. Meanwhile, the extracorporeal blood circulation needs to be used in a special hemodialysis machine or a blood perfusion machine, the cost is high, and the adsorption effect of harmful components in blood plasma cannot be improved under the condition that the whole blood circulation is not influenced.
In view of the above, it is necessary to design a plasma adsorption device for animal experiments to solve the above problems.
Disclosure of Invention
The invention aims to provide the plasma adsorption device for the animal experiment, which is simple and convenient to operate and low in use cost, can safely and effectively carry out the plasma adsorption treatment of the experimental animal, and can realize the cleaning and balance of the adsorption column under the condition of not influencing the whole blood circulation.
In order to achieve the above object, the present invention provides a plasma adsorption apparatus for animal experiments, comprising a whole blood circulation line including a first line, a fourth line connected to the first line through a membrane type plasma separator, and a third line connected to the fourth line through a second venous tank, and a plasma adsorption and adsorption column treatment line connected to the whole blood circulation line through a membrane type plasma separator and a second venous tank, the plasma adsorption and adsorption column treatment line including a second line and a fifth line connected to the second line; the first pipeline, the second pipeline and the third pipeline are respectively provided with a first pressure gauge, a second pressure gauge and a third pressure gauge; an adsorption column is arranged on the second pipeline, and one end, far away from the second pipeline, of the fifth pipeline is connected with a matched liquid bag.
As a further development of the invention, the first and second lines are also provided with a first peristaltic pump and a second peristaltic pump, respectively.
As a further improvement of the invention, the pressure difference of the first pipeline, the second pipeline and the third pipeline is in the range of 2-10KPa.
As a further improvement of the invention, the method for establishing the extracorporeal blood circulation channel is to use a double-vena cava catheter to conduct jugular vein catheterization.
As a further improvement of the invention, one end of the first pipeline far away from the membrane type plasma separator is connected with the arterial port of the double-cavity venous catheter.
As a further improvement of the invention, a first venous pot is also arranged on the first pipeline, and a sixth pipeline for anticoagulant addition is connected to the first venous pot.
As a further improvement of the invention, the adsorption column is filled with an immunoadsorbent taking agarose or cellulose as a carrier, and the tank volume of the adsorption column is 80-200 ml.
As a further improvement of the invention, the animal is an animal with a blood flow of 30ml/min or more.
As a further improvement of the invention, the flow rate of whole blood in the plasma adsorption device is 40-100 ml/min, and the flow rate of plasma is 8-20 ml/min.
As a further improvement of the invention, the whole blood circulation and the treatment part of the plasma adsorption and adsorption column are provided with a disposable blood circuit catheter for dialysis type artificial kidney.
The beneficial effects of the invention are as follows:
1. according to the invention, the plasma adsorption treatment process is divided into two parts of whole blood circulation and plasma adsorption and adsorption column treatment, and the whole blood circulation pipeline and the plasma adsorption and adsorption column treatment pipeline are correspondingly arranged, so that on one hand, the cleaning and balance of the adsorption column can be realized under the condition of not influencing the whole blood circulation, the adsorption effect of the adsorption column on harmful components in the plasma treatment process is ensured, on the other hand, the pipeline pressure monitoring of the first pipeline, the second pipeline and the third pipeline is carried out by combining the arrangement of the first pressure gauge, the second pressure gauge and the third pressure gauge, and the differential pressure of the three pipelines is controlled within a certain range by the first peristaltic pump and the second peristaltic pump, and the blood pressure drop caused by the pipeline differential pressure and the membrane rupture of the membrane type plasma separator are avoided, so that the plasma adsorption device disclosed by the invention can be suitable for the plasma adsorption treatment of animals with the blood flow of more than or equal to 30 ml/min.
2. After general anesthesia is carried out on the beagle dogs, a vascular access is established through the jugular vein by using the double-cavity venous catheter, so that the operation steps of establishing the vascular access of the experimental animal are simplified, the vascular access can be reserved for about one month, the plasma adsorption experiment can be repeatedly carried out on the same experimental animal, and the pain of the experimental animal caused by the vascular access establishment operation is relieved. Meanwhile, in the whole experimental process, the peristaltic pump is only needed to meet the power supply requirement, and a blood ventilation machine or a blood perfusion machine with a specific model is not needed, so that the experimental cost can be greatly reduced. In addition, the disposable blood circuit catheter of the dialysis type artificial kidney is used for conducting liquid, the use specification of the adsorption column can be increased, the adsorption column with normal specification can be connected for animal experiments, and experiments are not required to be conducted by self-made reduced adsorption column models, so that the accuracy and the reliability of experimental results are greatly improved.
Drawings
Fig. 1 is a schematic structural view of a plasma adsorption device for animal experiments according to the present invention.
Reference numerals
10. A first pipeline; 11. a first pressure gauge; 12. a first peristaltic pump; 13. a first venous pot; 14. a membrane type plasma separator; 20. a second pipeline; 21. a second pressure gauge; 22. a second peristaltic pump; 23. an adsorption column; 24. a waste water discharge line; 30. a third pipeline; 31. a third pressure gauge; 32. a second venous pot; 40. a fourth pipeline; 50. a fifth pipeline; 51. a matched liquid bag; 60. a sixth pipeline; 61. an anticoagulant.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in detail with reference to the accompanying drawings and specific embodiments.
It should be noted that, in order to avoid obscuring the present invention due to unnecessary details, only structures and/or processing steps closely related to aspects of the present invention are shown in the drawings, and other details not greatly related to the present invention are omitted.
In addition, it should be further noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
As shown in fig. 1, the present invention provides a plasma adsorption apparatus for animal experiments, comprising a whole blood circulation line including a first line 10, a fourth line 40 connected to the first line 10 through the membrane type plasma separator 14, and a third line 30 connected to the fourth line 40 through the second venous tank 32, and a plasma adsorption and column treatment line connected to the whole blood circulation line through the membrane type plasma separator 14 and the second venous tank 32, the plasma adsorption and column treatment line including a second line 20 and a fifth line 50 connected to the second line 20.
Specifically, the method for establishing the blood extracorporeal circulation path of the animal experiment comprises the steps of using a double-cavity vein catheter for jugular vein catheterization, wherein the double-cavity vein catheter is 5Fr or 7Fr; one end of the first pipeline 10 far away from the membrane type plasma separator 14 is connected with an arterial port of the double-cavity venous catheter, a first pressure gauge 11, a first peristaltic pump 12 and a first venous kettle 13 are further arranged on the first pipeline 10 in sequence, and a sixth pipeline 60 for adding an anticoagulant 61 is further connected to the first venous kettle 13. The anticoagulant 61 is delivered to the first venous tank 13 through the sixth pipeline 60 to be mixed with blood to participate in the circulation of whole blood and plasma, thereby achieving the external anticoagulation effect.
Specifically, one end of the second pipeline 20 is connected with the first pipeline 10 through the membrane type plasma separator 14, the other end of the second pipeline 20 is connected with the third pipeline 30 through the second venous kettle 32, a second pressure gauge 21, a second peristaltic pump 22 and an adsorption column 23 are arranged on the second pipeline 20 according to the plasma conveying direction, a fifth pipeline 50 is further connected between the second pressure gauge 21 and the second peristaltic pump 22 on the second pipeline 20, and a matched liquid bag 51 is arranged at one end, far away from the second pipeline 20, of the fifth pipeline 50 and used for cleaning and balancing the adsorption column 23; a waste water discharge line 24 is also connected to the second line 20 between the second venous tank 32 and the adsorption column 23 for cleaning the adsorption column 23 and balancing the discharge of waste water. When the plasma is adsorbed, the whole blood enters the membrane type plasma separator 14 through the first pipeline 10 to separate the blood forming component from the plasma, wherein the blood forming component flows into the second venous pot 32 through the fourth pipeline 40, the plasma is adsorbed through the second pipeline 20, and then is mixed with the blood forming component through the second venous pot 32, and flows into the animal body through the third pipeline 30; when the adsorption column 23 is required to be cleaned and balanced, through valve adjustment, after the whole blood passes through the membrane type plasma separator 14, the whole blood is not filtered out of the plasma, but is directly conveyed back to the animal body through the fourth pipeline 40 and the third pipeline 30, meanwhile, the cleaning liquid and the balance liquid are conveyed into the second pipeline 20 through the fifth pipeline 50, and flow into the adsorption column 23 to clean and balance the adsorption column 23, and the cleaning waste liquid flows out through the waste water discharge pipeline 24, and after the cleaning and balance of the adsorption column 23 are completed, the valve is adjusted to continue the adsorption of the plasma.
Specifically, a third pressure gauge 31 is provided on the third pipe 30. In the experimental process, the pressure difference between the first pipeline 10, the second pipeline 20 and the third pipeline 30 is controlled within the range of 2-10KPa by adjusting the first peristaltic pump 12 and the second peristaltic pump 22, so that the pressure difference between the pipelines is prevented from causing blood pressure drop and the membrane of the membrane type plasma separator 14 is prevented from being broken.
Specifically, the membrane area of the membrane type plasma separator 14 was 0.2m 2 Or 0.3m 2 The method comprises the steps of carrying out a first treatment on the surface of the The maximum flow rate range of the peristaltic pump is 200-400 ml/min; the range of the pressure gauge is-100 kPa to 100kPa; the volume of the tank body of the adsorption column 23 is 80-200 ml, and the column is filled with an immunoadsorbent taking agarose or cellulose as a carrier.
Specifically, the animal is an animal with blood flow of more than or equal to 30ml/min, and the whole body heparin is carried out before plasma adsorption; in the experiment, the flow rate of whole blood in the plasma adsorption device is 40-100 ml/min, and the flow rate of plasma is 8-20 ml/min.
Specifically, the whole blood circulation and the blood circuit catheter is a disposable blood circuit catheter for dialysis type artificial kidney.
The plasma adsorption device for animal experiments provided by the invention is described below with reference to specific examples.
Example 1
The plasma adsorption device for animal experiments is used for carrying out the plasma adsorption of beagle dogs, and comprises the following specific steps:
1. pre-flushing treatment of plasma adsorption device
(1) Preparing pre-flushing liquid: the regeneration liquid contains 2500IU/500mL of physiological saline 3000mL of heparin, 1000mL of physiological saline 12500IU/500mL of heparin and no physiological saline of heparin.
(2) Adsorption column pre-flushing
a. The adsorption column was pre-flushed with a regeneration liquid at a flow rate of 100ml/min, the regeneration liquid being used in an amount of about 1L.
b. The regeneration liquid bag was replaced with physiological saline, and the adsorption column was equilibrated with the physiological saline at a flow rate of 100ml/min, and the amount of physiological saline was about 1L.
c. The normal saline is replaced by normal saline containing 2500IU/500mL of heparin, and the adsorption column 23 is pre-flushed at the flow rate of 100mL/min, wherein the dosage is 1500mL; then the physiological saline containing 2500IU/500mL of heparin is replaced by the physiological saline containing 12500IU/500mL of heparin, the adsorption column 23 is pre-flushed with the dosage of 500mL at 50mL/min, and the adsorption column 23 is soaked in the physiological saline containing 12500IU/500mL of heparin for 10-20 min during the period, so that the adsorption column 23 is fully anticoagulated; finally, the physiological saline containing the heparin 12500IU/500mL is replaced by the physiological saline without the heparin, the adsorption column 23 is pre-flushed at the flow rate of 100mL/min, and the physiological saline containing the heparin is discharged, wherein the dosage is 200mL.
(3) Membrane type plasma separator pre-flushing
The membrane type plasma separator 14 was pre-washed with a physiological saline solution containing 2500IU/500mL heparin at a flow rate of 100mL/min in an amount of 1500mL; then the physiological saline containing 2500IU/500mL of heparin is replaced by the physiological saline containing 12500IU/500mL of heparin, and the membrane type plasma separator 14 is pre-flushed at 50mL/min with the dosage of 500mL, and the membrane type plasma separator 14 is soaked in the physiological saline containing 12500IU/500mL of heparin for 10-20 min during the period, so that the membrane type plasma separator 14 is fully anticoagulated; finally, the physiological saline containing heparin 12500IU/500mL is replaced by physiological saline without heparin, and the membrane type plasma separator 14 is pre-flushed at the flow rate of 100mL/min, and the physiological saline containing heparin is discharged, wherein the dosage is 200mL.
2. Pipeline connection
The adsorption column 23, the membrane type plasma separator 14, and the like are connected to the plasma adsorption apparatus for animal experiments according to the present invention.
3. Beagle puts pipe
General anesthesia was performed on beagle dogs using 0.2ml/kg of sultai 50, and then a double-lumen intravenous catheter was used to establish an extracorporeal blood circulation path.
4. In vitro plasma adsorption treatment of beagle dogs using a plasma adsorption device
(1) Anticoagulation: heparin anticoagulation is adopted, the initial dose is 0.3 mg-0.8 mg/kg, intravenous injection is carried out 10min before treatment, continuous pumping is carried out at 10-15 mg every half hour during treatment, and the addition is stopped 30min before treatment is finished.
(2) Starting a first peristaltic pump 12 to enable the whole blood flow rate to reach 50-60 ml/min, closing a plasma filtering channel in the membrane type plasma separator 14, and opening the plasma filtering channel when the membrane type plasma separator 14 and a whole blood circulation pipeline are completely full of blood and the conditions of normal circulation, such as no hemolysis or membrane rupture, and the like; the second peristaltic pump 22 is turned on to set the plasma flow rate to not more than 20% of the whole blood flow rate, so that the line pressure difference of the first line 10, the second line 20 and the third line 30 is controlled within the range of 2-10KPa to avoid blood pressure drop and rupture of the membrane type plasma separator 14. The adsorption time was 30min.
(3) Blood return: after the adsorption is finished, the plasma filtering channel is closed, the normal saline blood returning method is adopted, the normal saline is used for driving the plasma in the adsorption column 23 and the pipeline back into the animal body at the speed of 30-40 mL/min, and the normal saline consumption volume is about 200mL. In this process, the blood circulation side of the membrane plasma separator 14 continues to circulate blood.
(4) Regeneration balance
a. Regeneration: after passing through the membrane type plasma separator 14, whole blood is directly returned to the animal body through the fourth pipeline 40 and the third pipeline 30 through valve adjustment, meanwhile, the fifth pipeline 50, the second pipeline 20 and the waste water discharge pipeline 24 are sequentially communicated through valve adjustment, regeneration liquid is input into the second pipeline 20 through the fifth pipeline 50, the adsorption column 23 is regenerated and washed at the flow rate of 100ml/min, the consumption of the regeneration liquid is about 500ml, after 5 column volumes are washed, the washing waste liquid is stopped, and the washing waste liquid flows out through the waste water discharge pipeline 24.
b. Balance: the regeneration solution was replaced with normal saline, the adsorption column 23 was equilibrated at a flow rate of 100ml/min, the equilibration was stopped after 5 column volumes, and the line was adjusted back to plasma adsorption mode.
(5) Circulating adsorption of plasma
And (3) taking the steps (2) - (4) as a cycle, and performing cycle adsorption treatment for 3 times as 1 treatment course.
(6) End of treatment
The connection of the first tubing 10 to the double-lumen intravenous catheter is terminated to normal saline, and blood is collected from the double-lumen intravenous catheter for measuring blood normative, blood biochemical and blood coagulation indexes, at which time the first peristaltic pump 12 is suspended. After blood collection, the normal saline blood return method or the air blood return method is adopted to return blood, and adsorption treatment is finished.
And carrying out adsorption treatment on 6 beagle dogs according to the plasma adsorption step of the beagle dogs, wherein the treatment frequency is 2 times per week, and each beagle dog carries out adsorption treatment for 6 treatment courses, wherein each beagle dog can be repeatedly used after being subjected to first tube setting, and the tube setting is not required to be repeated. After the last treatment is finished, the experimental animal is continuously fed with the common feed for 7 days, and vital signs of the animal and whether adverse events exist or not are observed and recorded, such as the appearance, the behavioural activity, the mental state, the body temperature, the food intake, whether the respiration is normal or not and the like of the animal. Simultaneously, venous blood is collected before the first treatment and 7 days after the last treatment are finished, blood routine, blood biochemical and blood coagulation related index detection is carried out, the blood routine detection results are shown in table 1, the blood biochemical detection results are shown in table 2, and the blood coagulation related index detection results are shown in table 3.
TABLE 1 blood routine test results
Remarks: * Respectively, significant and very significant differences.
As can be seen from table 1, 7 days after completion of the treatment: red blood cells, hemoglobin, hematocrit, platelet count, and platelet specific volume increased by 12.01%, 9.24%, 12.33%, 114.03%, 92.86%, respectively; the proportion of neutrophils is reduced by 44.22%, and the average red blood cell hemoglobin content and the average red blood cell hemoglobin concentration are slightly reduced. After the placement and wound closure, the subject animal will have signs of mild inflammation at the wound site due to the impermeability of the wound dressing, etc. Therefore, during the course of treatment, the rise of blood cells associated with inflammation such as leukocytes, lymphocytes and monocytes occurs. After 7 days of treatment, the inflammation disappeared, and the number of cells associated with the inflammation was restored to normal. In addition, after the end of the treatment and during the follow-up period, the subject animals had increased hemoglobin, erythrocytes and platelets, but were still within normal values, presumably related to blood loss due to extracorporeal blood circulation and inflammatory responses during the treatment.
The changes of the blood routine index caused by treatment are all in the normal value range, and are mainly related to operation and extracorporeal blood circulation and are irrelevant to tested instruments, so that the plasma adsorption device for animal experiments does not cause obvious damage to tested animals.
TABLE 2 Biochemical blood test results
Remarks: * Respectively, significant and very significant differences.
As can be seen from table 2, 7 days after treatment: total cholesterol, triglyceride, low density lipoprotein cholesterol, potassium rise by 27.77%, 190.00%, 98.13%, 11.43%, respectively; sodium and chlorine are slightly reduced. For the variation of blood lipid in the test animals, the following reasons are presumed: the first is the effect of the non-specific adsorption of the agarose microspheres of the adsorption column 23, and the loss caused by the extracorporeal blood circulation itself; secondly, heparin not only has anticoagulation effect, but also has the effect of reducing blood fat; third is the effect of fasted animals on adsorption therapy and blood sampling. The slight change in the electrolyte is presumed to be related to the input of anticoagulation and physiological saline.
The change of blood biochemical index caused by treatment is related to catheterization operation and nonspecific adsorption, so that the plasma adsorption device for animal experiments does not cause obvious damage to tested animals.
TABLE 3 coagulation-related index detection results
Remarks: "-" indicates that the original value is below or above the instrument limit of detection and cannot be statistically analyzed.
Before the treatment is started, the tested animals need to be injected with physiological saline containing heparin sodium for initial dose anticoagulation, and during the treatment period, the physiological saline containing heparin sodium also needs to be continuously pumped in for preventing and treating coagulation. The pre-treatment coagulation results are thus either below or above the limit of detection of the instrument, or vary considerably, both due to infusion of anticoagulant 61. After 7 days of treatment, the coagulation indexes of the tested animals are restored to normal level, and the physiological activities of the tested animals are not affected.
Within 7 days after the final treatment is finished, the vital signs of the tested animals are stable, no obvious abnormality exists, and no serious adverse event occurs, which indicates that the plasma adsorption device for animal experiments does not cause obvious damage to the tested animals.
In summary, the plasma adsorption device for animal experiments disclosed by the invention divides a plasma adsorption treatment process into two parts, namely whole blood circulation and plasma adsorption and adsorption column treatment, and accordingly performs the whole blood circulation pipeline and the plasma adsorption and adsorption column treatment pipeline arrangement, on one hand, the cleaning and balance of the adsorption column 23 can be realized under the condition that the whole blood circulation is not affected, so as to ensure the adsorption effect of the adsorption column 23 on harmful components in the plasma treatment process, on the other hand, the arrangement of the first pressure gauge 11, the second pressure gauge 21 and the third pressure gauge 31 is utilized in combination, the pressure monitoring of the first pipeline 10, the second pipeline 20 and the third pipeline 30 is performed, and the pressure difference of the three pipelines is controlled within a certain range through the first peristaltic pump 12 and the second peristaltic pump 22, so that the pressure difference of the pipelines can be prevented from causing the blood pressure drop and the membrane of the membrane type separator 14 from being broken, and the plasma adsorption device disclosed by the invention can be suitable for the plasma adsorption treatment of animals with the blood flow of more than or equal to 30 ml/min. In addition, the plasma adsorption device is used for carrying out plasma adsorption, the operation is simple and can be repeatedly used, the pain of the operation on experimental animals can be greatly relieved, and meanwhile, a special blood ventilation machine or a blood perfusion machine is not required to be used for extracorporeal blood circulation, so that the test cost is low. The plasma adsorption device disclosed by the invention has no obvious change in basic vital sign and no obvious change in blood indexes before and after treatment when being used for carrying out plasma adsorption treatment on the beagle dogs, so that the plasma adsorption device can not cause obvious damage to tested animals, and can be safely used for the plasma adsorption treatment of animals.
The above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made thereto without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. A plasma adsorption equipment for animal experiments, its characterized in that: the plasma adsorption and adsorption column treatment pipeline comprises a first pipeline, a fourth pipeline connected with the first pipeline through the membrane type plasma separator and a third pipeline connected with the fourth pipeline through the second venous kettle, and the plasma adsorption and adsorption column treatment pipeline comprises a second pipeline and a fifth pipeline connected with the second pipeline; the first pipeline, the second pipeline and the third pipeline are respectively provided with a first pressure gauge, a second pressure gauge and a third pressure gauge; an adsorption column is arranged on the second pipeline, and one end, far away from the second pipeline, of the fifth pipeline is connected with a matched liquid bag.
2. The plasma adsorption device for animal experiments according to claim 1, wherein: the first pipeline and the second pipeline are also respectively provided with a first peristaltic pump and a second peristaltic pump.
3. The plasma adsorption device for animal experiments according to claim 2, wherein: the pressure difference range of the first pipeline, the second pipeline and the third pipeline is 2-10KPa.
4. The plasma adsorption device for animal experiments according to claim 1, wherein: the method for establishing the extracorporeal blood circulation channel is to use a double-cavity vein catheter to conduct jugular vein catheterization.
5. The plasma adsorption device for animal experiments according to claim 4, wherein: one end of the first pipeline, which is far away from the membrane type plasma separator, is connected with the arterial port of the double-cavity venous catheter.
6. The plasma adsorption device for animal experiments according to claim 5, wherein: the first pipeline is also provided with a first venous pot, and a sixth pipeline for adding an anticoagulant is connected to the first venous pot.
7. The plasma adsorption device for animal experiments according to claim 1, wherein: the adsorption column is filled with an immunoadsorbent taking agarose or cellulose as a carrier, and the volume of a tank body of the adsorption column is 80-200 ml.
8. The plasma adsorption device for animal experiments according to claim 1, wherein: the animal is an animal with blood flow not less than 30 ml/min.
9. The plasma adsorption device for animal experiments according to claim 1, wherein: the flow rate of whole blood in the plasma adsorption device is 40-100 ml/min, and the flow rate of plasma is 8-20 ml/min.
10. The plasma adsorption device for animal experiments according to claim 1, wherein: the whole blood circulation and the treatment part of the plasma adsorption and adsorption column are provided with a disposable blood circuit catheter for dialysis type artificial kidney.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211674644.XA CN115998974A (en) | 2022-12-26 | 2022-12-26 | Plasma adsorption device for animal experiments |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211674644.XA CN115998974A (en) | 2022-12-26 | 2022-12-26 | Plasma adsorption device for animal experiments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115998974A true CN115998974A (en) | 2023-04-25 |
Family
ID=86027629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211674644.XA Pending CN115998974A (en) | 2022-12-26 | 2022-12-26 | Plasma adsorption device for animal experiments |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115998974A (en) |
-
2022
- 2022-12-26 CN CN202211674644.XA patent/CN115998974A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102389594B (en) | Portable blood purifying system | |
| WO2013019994A2 (en) | Hemodialysis system having a flow path with a controlled compliant volume | |
| CN103505766A (en) | Metabolic detoxification system and method | |
| CA1124952A (en) | Method and apparatus for continuous, ambulatory peritoneal dialysis | |
| EP4073254A1 (en) | Extracorporeal blood treatment systems and methods employing batch processing | |
| CN202207346U (en) | Portable blood purifying system | |
| CN115998974A (en) | Plasma adsorption device for animal experiments | |
| CN106267418A (en) | Female tire blood group incompatibility antibody adsorbing therapy instrument | |
| CN101164628A (en) | Device for purifying blood and application thereof | |
| WO2019153848A1 (en) | Versatile plasma purification system based on centrifugal plasma separation method | |
| CN106110424A (en) | Female tire Rh blood group incompatibility immunoadsorption therapy instrument | |
| CN203677608U (en) | Device for adopting CRRT machine to perform blood purification united ascites ultra-filtration reinfusion | |
| CN204543038U (en) | The external arterial line of front dilution method hemofiltration and circulation line | |
| Schmidt et al. | Plasmapheresis without pumps for therapeutic and donor purposes | |
| CN211301424U (en) | Special blood purification system of children | |
| JPS5921813Y2 (en) | Blood granulocyte collection filter | |
| Khoo et al. | Hypoglycemia in nondiabetic patients undergoing albumin dialysis by molecular adsorbent recirculating system | |
| CN217140768U (en) | Centrifugal plasma immunoadsorption treatment device | |
| CN106267421A (en) | Female fetal blood type does not conforms to blood plasma depurator | |
| CN206167483U (en) | Hemodialysis of nephrology dept. device | |
| Bem et al. | Ammonium removal with a novel zirconium silicate | |
| CN113521418A (en) | Double-filtration adsorption plasma replacement system | |
| CN111529784A (en) | CPFA (coherent population FA) bridging pipeline | |
| Moran | Use of the LifeSite® hemodialysis access system improves blood flow and access patency | |
| Liao et al. | Modeling of Dialysate Flow in an Artificial Kidney: A Porous Media Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Mang Inventor after: Wu Huan Inventor after: Wang Yefu Inventor before: Wang Mang Inventor before: Zhou Qi Inventor before: Wu Huan Inventor before: Zhang Lei Inventor before: Wang Yefu |
|
| CB03 | Change of inventor or designer information |